NASDAQ:COLL Collegium Pharmaceutical Q2 2025 Earnings Report $31.20 -1.06 (-3.29%) Closing price 04:00 PM EasternExtended Trading$31.20 0.00 (-0.02%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Collegium Pharmaceutical EPS ResultsActual EPSN/AConsensus EPS $1.88Beat/MissN/AOne Year Ago EPSN/ACollegium Pharmaceutical Revenue ResultsActual RevenueN/AExpected Revenue$182.26 millionBeat/MissN/AYoY Revenue GrowthN/ACollegium Pharmaceutical Announcement DetailsQuarterQ2 2025Date8/14/2025TimeBefore Market OpensConference Call DateThursday, August 7, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Collegium Pharmaceutical Earnings HeadlinesUnpacking Q1 Earnings: Organon (NYSE:OGN) In The Context Of Other Branded Pharmaceuticals StocksJuly 18 at 2:44 PM | msn.comCollegium Pharmaceutical (NASDAQ:COLL) to Repurchase $150.00 million in Outstanding Stock July 9, 2025 | americanbankingnews.comThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the same point in every cycle when crypto enters its most explosive phase — and two experts are showing how to ride it. Inside The Crypto Code Workshop, you’ll get their step-by-step system and $10 in free Bitcoin for attending.July 18 at 2:00 AM | Crypto Swap Profits (Ad)Collegium Pharmaceutical Breaks Above 200-Day Moving Average - NasdaqJuly 8, 2025 | nasdaq.comCollegium Pharma Launches Up To $150 Mln Buyback Program; Stock Up In Pre-market - NasdaqJuly 8, 2025 | nasdaq.comCollegium Announces $150 Million Share Repurchase ProgramJuly 7, 2025 | globenewswire.comSee More Collegium Pharmaceutical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Collegium Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Collegium Pharmaceutical and other key companies, straight to your email. Email Address About Collegium PharmaceuticalCollegium Pharmaceutical (NASDAQ:COLL) is a specialty pharmaceutical company focused on the development and commercialization of improved therapies for patients suffering from pain. The company’s core business revolves around creating and marketing abuse-deterrent and extended-release opioid formulations designed to address the clinical complexities of chronic pain management while mitigating risks associated with opioid misuse. Through its proprietary DETERx platform, Collegium aims to deliver consistent, controlled drug release and reduced potential for tampering or diversion. The company’s flagship product, Xtampza ER, is an extended-release oxycodone capsule approved for the management of chronic, moderate to severe pain in patients requiring continuous, long-term opioid treatment. Beyond Xtampza ER, Collegium maintains an active development pipeline of additional formulations built on its DETERx technology, targeting both oral and potential non‐oral delivery routes. The company also invests in clinical and real-world studies to demonstrate the safety, efficacy, and abuse-deterrent properties of its product candidates, supporting prescriber confidence and payer access. Founded in 2013 as a spin-out from Rhodes Technologies, Collegium Pharmaceutical is headquartered in Wilmington, North Carolina, and serves patients and healthcare providers across the United States. Over the years, the company has expanded its commercial infrastructure, establishing sales and medical affairs teams dedicated to pain management. Collegium is led by Chief Executive Officer Michael Thomas and a management team with deep expertise in pharmaceutical development, regulatory affairs, and commercial strategy, underscoring its commitment to advancing patient-centered pain therapies.Written by Jeffrey Neal JohnsonView Collegium Pharmaceutical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025)General Motors (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
